Isaac Barchas Sells 20,840 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 20,840 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40. Following the completion of the transaction, the director owned 87,664 shares in the company, valued at $2,284,523.84. This represents a 19.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $397,362.88.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Up 2.6%

NASDAQ IMNM traded up $0.66 on Monday, reaching $25.69. 1,228,372 shares of the stock traded hands, compared to its average volume of 1,385,460. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -10.79 and a beta of 2.07. The firm’s fifty day simple moving average is $21.49 and its 200 day simple moving average is $22.16. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $27.65.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities research analysts forecast that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IMNM. HC Wainwright restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners lowered their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Truist Financial lifted their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Finally, Barclays initiated coverage on Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.18.

Hedge Funds Weigh In On Immunome

Institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Immunome in the 1st quarter worth about $60,000. Strs Ohio purchased a new position in shares of Immunome during the 4th quarter valued at $64,000. Assetmark Inc. lifted its position in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares in the last quarter. State of Wyoming purchased a new stake in Immunome during the second quarter valued at approximately $109,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in Immunome during the fourth quarter worth $121,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.